These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35125346)

  • 1. A High-Throughput Screening Assay to Identify Drugs that Can Treat Long QT Syndrome Caused by Trafficking-Deficient K
    Egly CL; Blackwell DJ; Schmeckpeper J; Delisle BP; Weaver CD; Knollmann BC
    Mol Pharmacol; 2022 Apr; 101(4):236-245. PubMed ID: 35125346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The proteostasis interactomes of trafficking-deficient variants of the voltage-gated potassium channel K
    Egly CL; Barny LA; Do T; McDonald EF; Knollmann BC; Plate L
    J Biol Chem; 2024 Jul; 300(7):107465. PubMed ID: 38876300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-throughput discovery of trafficking-deficient variants in the cardiac potassium channel K
    Kozek KA; Glazer AM; Ng CA; Blackwell D; Egly CL; Vanags LR; Blair M; Mitchell D; Matreyek KA; Fowler DM; Knollmann BC; Vandenberg JI; Roden DM; Kroncke BM
    Heart Rhythm; 2020 Dec; 17(12):2180-2189. PubMed ID: 32522694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological correction of long QT-linked mutations in KCNH2 (hERG) increases the trafficking of Kv11.1 channels stored in the transitional endoplasmic reticulum.
    Smith JL; Reloj AR; Nataraj PS; Bartos DC; Schroder EA; Moss AJ; Ohno S; Horie M; Anderson CL; January CT; Delisle BP
    Am J Physiol Cell Physiol; 2013 Nov; 305(9):C919-30. PubMed ID: 23864605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism.
    Anderson CL; Delisle BP; Anson BD; Kilby JA; Will ML; Tester DJ; Gong Q; Zhou Z; Ackerman MJ; January CT
    Circulation; 2006 Jan; 113(3):365-73. PubMed ID: 16432067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of loss of Kv11.1 K+ current in mutant T421M-Kv11.1-expressing rat ventricular myocytes: interaction of trafficking and gating.
    Balijepalli SY; Lim E; Concannon SP; Chew CL; Holzem KE; Tester DJ; Ackerman MJ; Delisle BP; Balijepalli RC; January CT
    Circulation; 2012 Dec; 126(24):2809-18. PubMed ID: 23136156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long QT Syndrome Type 2: Emerging Strategies for Correcting Class 2
    Ono M; Burgess DE; Schroder EA; Elayi CS; Anderson CL; January CT; Sun B; Immadisetty K; Kekenes-Huskey PM; Delisle BP
    Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32759882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rescue of expression and function of long QT syndrome-causing mutant hERG channels by enhancing channel stability in the plasma membrane.
    Davis J; Cornwell JD; Campagna N; Guo J; Li W; Yang T; Wang T; Zhang S
    J Biol Chem; 2024 Aug; 300(8):107526. PubMed ID: 38960041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trafficking defect and proteasomal degradation contribute to the phenotype of a novel KCNH2 long QT syndrome mutation.
    Mihic A; Chauhan VS; Gao X; Oudit GY; Tsushima RG
    PLoS One; 2011 Mar; 6(3):e18273. PubMed ID: 21483829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional Invalidation of Putative Sudden Infant Death Syndrome-Associated Variants in the
    Smith JL; Tester DJ; Hall AR; Burgess DE; Hsu CC; Elayi SC; Anderson CL; January CT; Luo JZ; Hartzel DN; Mirshahi UL; Murray MF; Mirshahi T; Ackerman MJ; Delisle BP
    Circ Arrhythm Electrophysiol; 2018 May; 11(5):e005859. PubMed ID: 29752375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanistic basis for type 2 long QT syndrome caused by KCNH2 mutations that disrupt conserved arginine residues in the voltage sensor.
    McBride CM; Smith AM; Smith JL; Reloj AR; Velasco EJ; Powell J; Elayi CS; Bartos DC; Burgess DE; Delisle BP
    J Membr Biol; 2013 May; 246(5):355-64. PubMed ID: 23546015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel intracellular transport-refractory mutations in KCNH2 identified in patients with symptomatic long QT syndrome.
    Fukumoto D; Ding WG; Wada Y; Fujii Y; Ichikawa M; Takayama K; Fukuyama M; Kato K; Itoh H; Makiyama T; Omatsu-Kanbe M; Matsuura H; Horie M; Ohno S
    J Cardiol; 2018 Apr; 71(4):401-408. PubMed ID: 29146210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional and clinical characterization of a novel homozygous KCNH2 missense variant in the pore region of Kv11.1 leading to a viable but severe long-QT syndrome.
    Delinière A; Jaupart L; Janin A; Millat G; Boulin T; Andrini O; Chevalier P
    Gene; 2024 Mar; 897():148076. PubMed ID: 38086455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential Effects of Remdesivir and Lumacaftor on Homomeric and Heteromeric hERG Channels.
    Campagna N; Wall E; Lee K; Guo J; Li W; Yang T; Baranchuk A; El-Diasty M; Zhang S
    Mol Pharmacol; 2023 Oct; 104(4):164-173. PubMed ID: 37419691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of protein quality control of the human ether-à-go-go related gene K
    Ledford HA; Ren L; Thai PN; Park S; Timofeyev V; Sirish P; Xu W; Emigh AM; Priest JR; Perez MV; Ashley EA; Yarov-Yarovoy V; Yamoah EN; Zhang XD; Chiamvimonvat N
    Heart Rhythm; 2022 Feb; 19(2):281-292. PubMed ID: 34634443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of CAV3 in long-QT syndrome: clinical and functional assessment of a caveolin-3/Kv11.1 double heterozygote versus caveolin-3 single heterozygote.
    Hedley PL; Kanters JK; Dembic M; Jespersen T; Skibsbye L; Aidt FH; Eschen O; Graff C; Behr ER; Schlamowitz S; Corfield V; McKenna WJ; Christiansen M
    Circ Cardiovasc Genet; 2013 Oct; 6(5):452-61. PubMed ID: 24021552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of Kv11.1 potassium channel PAS-domain variants trafficking via machine learning.
    Immadisetty K; Fang X; Ramon GS; Hartle CM; McCoy TP; Center RG; Mirshahi T; Delisle BP; Kekenes-Huskey PM
    J Mol Cell Cardiol; 2023 Jul; 180():69-83. PubMed ID: 37187232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacologically validated, high-capacity, functional thallium flux assay for the human Ether-à-go-go related gene potassium channel.
    Schmalhofer WA; Swensen AM; Thomas BS; Felix JP; Haedo RJ; Solly K; Kiss L; Kaczorowski GJ; Garcia ML
    Assay Drug Dev Technol; 2010 Dec; 8(6):714-26. PubMed ID: 21158686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting.
    Huang XP; Mangano T; Hufeisen S; Setola V; Roth BL
    Assay Drug Dev Technol; 2010 Dec; 8(6):727-42. PubMed ID: 21158687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LUF7244 plus Dofetilide Rescues Aberrant K
    Qile M; Ji Y; Golden TD; Houtman MJC; Romunde F; Fransen D; van Ham WB; IJzerman AP; January CT; Heitman LH; Stary-Weinzinger A; Delisle BP; van der Heyden MAG
    Mol Pharmacol; 2020 Jun; 97(6):355-364. PubMed ID: 32241959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.